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Abstract 
The calcitonin gene-related peptide (CGRP) family of 
G protein-coupled receptors (GPCRs) is formed 
through association of the calcitonin receptor-like 
receptor (CLR) and one of three receptor activity-
modifying proteins (RAMPs). Binding of one of the 
three peptide ligands, CGRP, adrenomedullin (AM) or 
intermedin/adrenomedullin2 (AM2) is well known to 
result in a Gαs-mediated increase in cAMP. Here we 
use modified yeast strains that couple receptor 
activation to cell growth, via chimeric yeast/Gα 
subunits, and HEK-293 cells to characterize the effect 
of different RAMP and ligand combinations on this 
pathway. We not only demonstrate functional 
couplings to both Gαs and Gαq but also identify a Gαi 
component to CLR signaling in both yeast and HEK-
293 cells, which is absent in HEK-293S cells. We 
show that the CGRP family of receptors displays both 
ligand and RAMP-dependent signaling bias between 
Gαs, Gαi and Gαq/11 pathways. The results are 
discussed in the context of RAMP interactions probed 
through molecular modelling and molecular dynamics 
simulations of the RAMP-GPCR-G protein 
complexes. This study further highlights the 
importance of RAMPs to CLR pharmacology, and to 
bias in general, as well as identifying the importance 
of choosing an appropriate model system for the study 
of GPCR pharmacology. 
 
 
Introduction 
Calcitonin gene-related peptide (CGRP), 
adrenomedullin (AM) and adrenomedullin 2 (AM2, 
also known as intermedin) are members of the 
calcitonin peptide family (1). This family also 
includes calcitonin and amylin. CGRP is an extremely 
abundant neuropeptide, widely distributed throughout 
the sensory nervous system. It is a very potent 
vasodilator, released during neurogenic inflammation 
and is particularly implicated in the onset of migraine. 
It is also cardioprotective and is associated with both 
pro- and anti-inflammatory actions (2-3). AM is 
produced by the vascular endothelium and has 
extensive effects on the cardiovascular system 
including stimulation of angiogenesis and the 
modulation of vascular tone (4-6). AM2 affects the 
vascular system in a similar manner to AM (7-9). Like 
CGRP, AM and AM2 are also cardioprotective and 
their administration results in decreased blood 
pressure and increased speed of recovery from 
myocardial infarction (10-11).  
 CGRP, AM and AM2 activate three receptors 
which share a common class B G protein-coupled 
receptor (GPCR) subunit, the calcitonin receptor-like 
receptor (CLR) (12). In each receptor CLR forms a 
heterodimer with receptor activity-modifying proteins 
(RAMPs) 1, 2 or 3. The formation of this heterodimer 
is obligatory for receptor function and efficient 
translocation of both subunits to the cell surface (13). 
Heterodimerisation with RAMP 1, 2 or 3 forms the 
CGRP, AM1 or AM2 receptors respectively (13). The 
peptides ligands activate each receptor with differing 
potencies (1, 12).  
Activation of all three CLR-based receptors 
by CGRP, AM or AM2 generates increased cAMP 
production through coupling to the stimulatory G 
protein, Gαs (1, 12, 14). However, CGRP, AM and 
AM2 can signal through other pathways (1, 15-16). 
Several studies have indicated that the CGRP family 
of receptors can also couple to Gαi/o subunits, since 
their cAMP responses can be significantly increased 
through treatment with pertussis toxin (PTX), 
particularly in electrically excitable cells (17-20). The 
AM/AM2 receptor cAMP signaling in HEK-293 cells 
has also been shown to be PTX sensitive (21). The 
existing information on stimulation of signaling by 
CGRP, AM or AM2 other than through the Gαs-
cAMP pathway has been predominantly gained from 
physiological studies and the relative signaling bias of 
CGRP, AM and AM2 at the three CLR-based 
receptors, even for the cAMP pathway, remains to be 
determined.  
The study of signaling bias in vivo is 
complicated by crosstalk from the wide range of 
signaling pathways present in certain cell lines or 
primary cell cultures. The Saccharomyces cerevisiae 
growth system (22) provides a robust assay to enable 
the examination of the coupling of a GPCR of choice 
to single G protein subunits. This is achieved through 
replacing the last 5 amino acids of the native yeast G 
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protein with the corresponding sequence from the 
human G protein of choice. (22-23). This assay has 
recently been successfully employed to characterize 
the signaling pathways underlying the glucagon-like 
peptide 1 (GLP-1) receptor response to GLP-1 and the 
many receptor agonist mimetics available (24-25). 
Miret and co-workers in 2002, very elegantly 
described the functional expression of the CLR with 
RAMP1 and RAMP2 in yeast (26). However, 
somewhat surprisingly, given the more recent interest 
in signaling bias, further characterization of RAMP-
CLR combinations in yeast has not been performed.  
In this study we have utilized S. cerevisiae to 
express either RAMP1, 2 or 3 along with CLR in 
order to assess the coupling of the three CGRP family 
receptors to different human Gα subunits upon 
stimulation with either CGRP, AM or AM2. We 
demonstrate that all members of the CGRP receptor 
family successfully couple to GPA1/Gαs, GPA1/Gαi 
and GPA1/Gαq yeast chimeras and that the coupling 
preference of each receptor is dependent upon the 
stimulating ligand. The results obtained from the yeast 
system were verified in HEK-293 mammalian cell 
lines by the assessment of cAMP accumulation 
(which showed sensitivity to PTX) and mobilizations 
of intracellular calcium (i(Ca2+)). The data confirm 
that RAMPs alter the ability of each peptide to couple 
to G proteins; it also indicates that the G proteins 
influence the rank order of agonist potency at the 
different receptors. For CGRP, AM and AM2 this 
means that potent activation of what would not 
generally be considered their ‘normal’ receptors can 
be observed when alternative downstream pathways, 
such as stimulation of Gαi, or mobilizations of i(Ca2+) 
are considered.  
Considerable understanding has been gained 
into class B GPCR structure, function and dynamics 
(27), primarily through molecular dynamic 
simulations (28-32). Consequently, in order to gain 
insight into possible mechanisms behind our 
experimental results, we have used molecular 
modelling and molecular dynamics simulations of 
RAMP complexes with CLR and the glucagon 
receptor (GCGR) to suggest a mechanism whereby 
the C-terminal tail of the RAMPs may influence G 
protein bias at the CLR. Finally we demonstrate that 
care is required when selecting an appropriate 
mammalian cell line to use when investigating G 
protein-bias since analysis of a HEK-293S cell line 
failed to show any Gαi-coupling for any of the 
RAMP-CLR complexes thus highlighting that agonist 
bias can be directly influenced by the cellular 
background.  
 
Results 
Gαs coupling of CLR-based receptors - We 
co-expressed CLR under the control of the strong 
PGK promoter, with RAMP1, RAMP2 or RAMP3 
independently in a yeast strain containing a chimeric 
Gα-subunit in which the C-terminal 5 amino acids of 
GPA1 had been replaced with those of mammalian 
Gαs, in order to study the coupling of the resultant 
receptors to a system expressing just a single G 
protein. Concentration-response curves were 
constructed for growth of S. cerevisiae for each 
RAMP-CLR combination (i.e. the CGRP, AM1 and 
AM2 receptors) using the agonists CGRP, AM and 
AM2. When CLR was co-expressed with RAMP1 all 
three ligands appeared to generate an equivalent level 
of response but with differing potencies (Figure 1A; 
Table 1). This generates a rank order of potency for 
the three ligands of CGRP > AM > AM2. Application 
of the operational model of pharmacological agonism 
(34) indicates that all three ligands exhibit similar 
efficacies (log τ) in yeast when CLR and RAMP1 are 
co-expressed (Figure 1D; Table 1). RAMP2 co-
expression with CLR generated a functional receptor 
(Figure 1B) with rank ligand potencies of AM > AM2 
= CGRP. AM2 appeared to behave as a partial agonist 
with a reduced log τ at the RAMP2-CLR heterodimer 
when compared to the other peptide agonists (Table 
1). AM had a significantly higher efficacy (p < 0.05) 
than that displayed by CGRP. Expression of RAMP3 
with CLR in S. cerevisiae generated a functional 
receptor where all three ligands activated GPA1/Gαs 
coupled signaling with similar potencies and 
efficacies (Figure 1C).  
We sought to confirm the pharmacology 
observed in the S. cerevisiae growth assay of the 
RAMP-CLR complexes in mammalian cell lines. For 
this we have used HEK-293 cells that do not 
functionally express any RAMPs (25). Co-
transfection of CLR and RAMP1 generated a rank 
order of ligand potency of CGRP >> AM = AM2. The 
rank order of ligand potency with co-transfection of 
CLR and RAMP2 was AM > CGRP >> AM2 and for 
CLR and RAMP3 was AM2 = AM > CGRP (Figure 
2, Table 2). It is worth noting that, in our HEK-293 
cells, only AM acts as a full agonist against the CLR 
when in complex with either RAMP2 or RAMP3. 
Overall the mammalian and yeast data show similar 
results with the most potent ligand at each receptor 
remaining the same in each case.  
Gαi coupling of CLR-based receptors - To 
address the possibility that the CGRP family of 
receptors may couple not only to Gαs but also to other 
subunits we returned to the S. cerevisiae growth 
assay. In this case the yeast strain used contained a 
chimeric GPA1/Gα subunit including the last 5 
residues of mammalian Gαi. We once again 
constructed concentration-response curves for yeast 
growth to the three agonists, CGRP, AM and AM2. 
The co-expression of CLR and RAMP1 resulted in 
similar potencies for CGRP, AM and AM2, (Table 1) 
however, AM and AM2 displayed significantly 
increased efficacies relative to CGRP for activation of 
GPA1/Gαi  (Table 1; Figure 3A and D). In contrast, 
when RAMP2 and CLR are co-transformed into the 
GPA1/Gαi yeast strain the rank order of ligand 
potency for GPA1/Gαi yeast-based growth was CGRP 
> AM = AM2 (Table 1, Figure 3B). AM2 showed a 
significantly decreased efficacy compared with the 
other peptides (Table 1, Figure 3D). Similarly to the 
RAMP1-CLR heterodimer, the combination of CLR 
and RAMP3 expressed in the GPA1/Gαi strain 
resulted in similar potencies for CGRP, AM and AM2 
(Table 1, Figure 3C). However, AM2 displayed a 
significantly reduced efficacy when compared to AM 
(Table 1, Figure 3D). 
In mammalian cells the Gαs and Gαi subunits 
act in opposition to regulate cAMP production. 
Therefore if a receptor can couple to both subunits in 
mammalian cells, the cAMP response measured is the 
result of a combination of the contribution from both 
pathways. Treatment of cells with PTX has been 
shown to uncouple receptors from the Gαi subunit and 
therefore remove any inhibition of cAMP production. 
We sought to confirm the apparent Gαs-Gαi coupling 
bias exhibited by the different RAMP-CLR 
combinations in the yeast reporter strains by 
measuring cAMP production from transiently 
transfected mammalian cells following PTX 
treatment. 
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Pre-treatment of HEK-293 cells co-expressing 
RAMP1 with the CLR resulted in little overall 
increases in CGRP-mediated cAMP production 
(Figure 4A). However, a significant elevation in Emax 
was observed in the same PTX-treated, RAMP1-CLR 
expressing cells, when challenged with either AM or 
AM2 (Figure 4, Table 3) suggesting that a Gαi 
component for both these ligands had been removed 
(Table 3). HEK-293 cells expressing CLR with either 
RAMP2 (Figure 4B) or RAMP3 (Figure 4C) 
displayed PTX-induced increases in Emax for cAMP 
accumulation, following stimulation with both CGRP 
and AM2 (Table 3). However, for both combinations, 
the AM response appeared to be unaffected by PTX 
treatment, suggesting that little Gαi coupling was 
present. Indeed, it is worth noting, that the cognate 
ligand for each receptor (CGRP for RAMP1-CLR and 
AM for RAMP2-CLR or RAMP3-CLR) did not 
appear to display an increased Emax upon PTX-
treatment, suggesting limited Gαi components in these 
cases. Importantly, PTX treatment of un-transfected 
HEK-293 cells did not result in a change in overall 
levels of cAMP accumulation as determined by 
forskolin stimulation (untreated = 16.57 ± 2.5 pmol 
cell-1; treated = 16.45 ± 2.4 pmol cell-1) thereby 
confirming that the effects observed were specific to 
the RAMP-CLR combinations. Thus, there is 
abundant evidence that receptor and ligands can 
activate Gαi in a mammalian cell, albeit in a complex 
pattern.  
Cell line variability in G protein expression - 
The HEK-293 human cell lineage has undergone a 
number of modifications (35). One such lineage, 
HEK-293S was adapted for growth in suspension 
(36). Interestingly, HEK-293S lines have also been 
reported to lack expression of RAMPs and therefore 
provide an alternative background for investigating 
the modulation of GPCR signal transduction (37, 38). 
Given that previous reports have suggested that some 
of the effects observed with RAMPs are cell-type 
dependent (37, 39), we utilized HEK-293S cells as an 
alternative cell line. Surprisingly, and in contrast to 
that observed for HEK-293 cells, HEK-293S cells 
pre-treated with PTX and co-expressing either 
RAMP1, RAMP2 or RAMP3 with CLR failed to 
demonstrate any significant change in either potency 
or Emax when challenged with CGRP, AM or AM2 
(Figure 5 A-C and Table 4; compare with Figure 4 A-
C). These results suggest that in HEK-293S cells, the 
RAMP-CLR combinations display little Gαi-mediated 
responses. This led us to speculate about the 
respective G protein content for the two cell lines. 
Using semi-quantitative RT-PCR we assessed the 
expression of twelve Gα subunits (Figure 6 A and B) 
in both mammalian cell lines. In the HEK-293 cells 
we were able to detect the expression of 10 Gα 
subunits, with a profile similar to that previously 
documented for these cells (40). Transcripts were not 
detectable for Gα14 or Gα15 subunits. Interestingly, in 
comparison to the HEK-293 cells, the HEK-293S 
cells displayed significantly lower expression of two 
Gαi subunits (relative to GAPDH) but broadly similar 
levels of all others Gα subunits. Furthermore, there 
was a much better correlation between the pEC50 
values for the ligands on HEK-293 and HEK-293S 
cells when the former had been pretreated with PTX, 
to remove the Gαi component, suggesting that the 
differences in Gαi expression between the two cell 
lines does have functional significance (Figure 6C, r = 
0.80 (95% confidence interval 0.27 to 0.96) with PTX 
v 0.52 (95% confidence interval -0.22 to 0.89) 
without PTX; p < 0.05). Importantly, this data 
demonstrates the need for caution when choosing 
cells for assessing G protein-mediated signaling 
responses.  
Gαq/11 coupling of CLR-based receptors – To 
provide a complete investigation of the G protein 
coupling of the RAMP-CLR complexes we extended 
our study to include the remaining 9 GPA1/Gα yeast 
chimera-expressing strains. Coupling with the RAMP-
CLR heterodimers was only observed in one 
additional strain that representing Gαq (strain 
MMY89). Concentration-response curves were 
generated (Figure 7 A-C, Table 1), demonstrating at 
RAMP1-CLR all three ligands displayed similar 
potencies, with CGRP being the most efficacious (log 
τ, Table 1), as expected for the cognate ligand at this 
receptor. AM2 is the most potent ligand when 
activating the RAMP2-CLR complex, whilst having a 
reduced Emax and log τ, relative to CGRP and AM 
(Table 1). With RAMP3-CLR a rank order of ligand 
potency of AM>AM2>CGRP was observed (Figure 
7C, Table 1), with all three ligands displaying broadly 
similar efficacies (Table 1).  
Ligand-engendered G protein bias - To 
provide a means by which to determine the relative 
bias each agonist displays at each RAMP-CLR 
complex for the three different chimeric G proteins (in 
yeast) we calculated the bias factor (expressed as 
ΔΔ(τ/Ka)) (41). For the RAMP1-CLR heterodimer 
values were calculated relative to CGRP, whereas 
when CLR was expressed with RAMP2 or RAMP3 
the reference ligand was AM. In all cases the 
reference pathway used was GPA1/Gαs (Figure 7E). 
The bias plots demonstrated that at the RAMP1-CLR 
complex AM2 shows a much greater bias towards 
signaling via GPA1/Gαi and GPA1/Gαq, relative to 
CGRP, whilst AM shows a bias profile approximately 
equal to CGRP. With RAMP2-CLR however, CGRP 
shows a much greater bias towards GPA1/Gαi 
signaling over GPA1/Gαs and GPA1/Gαq, whilst AM2 
is more biased towards GPA1/Gαq. In the presence of 
RAMP3 all three ligands are equally biased towards 
GPA1/Gαs and GPA1/Gαi, but CGRP and AM are less 
biased towards GPA1/Gαq signaling, relative to AM2. 
Activation of RAMP-CLR complexes leads to 
mobilization of intracellular Ca2+ in mammalian cells 
- In order to confirm our findings from S. cerevisiae 
we again utilized HEK 293 cells transiently 
expressing the CLR in conjunction with each RAMP, 
and measured release of i(Ca2+) upon stimulation with 
CGRP, AM and AM2. Whilst all three ligands 
resulted in calcium mobilization at each RAMP-CLR 
complex (Figure 8, Table 5), these results differed 
slightly from that observed in S. cerevisiae. At both 
RAMP1 and RAMP2-CLR a rank order of ligand 
potency of CGRP=AM>AM2 was seen, whilst CGRP 
was the most efficacious ligand (Table 5). With 
RAMP3-CLR both AM and AM2 were equipotent, 
with CGRP being the least potent agonist. Treatment 
with PTX was seen to have no effect upon the levels 
of calcium released in response to the three ligands, at 
any RAMP:CLR complex. 
To confirm our yeast findings that the CLR 
can couple to Gαq and thereby promote i(Ca2+) 
mobilization in mammalian cells, we utilized the 
known selective Gαq/11 inhibitor YM-254890 (42). 
Pre-treatment with YM-254890 for 30 min prior to 
stimulation with AM and AM2 was sufficient to 
abolish all i(Ca2+) mobilization at all RAMP-CLR 
complexes. Furthermore responses to CGRP at all 3 
RAMP-CLR complexes was also considerably 
attenuated with i(Ca2+) release only being detected 
when cells were stimulated with CGRP in the 
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micromolar range. Similar data was obtained using 
HEK 293S cells (Table 5) suggesting that despite 
differences in Gαi content, release of i(Ca2+) is 
consistent between the 2 cell types. These finding 
suggest that all three ligands are able to initiate 
calcium mobilization at all three RAMP-CLR 
complexes in a Gαq-dependent manner, in both 
mammalian cell lines. 
Pathway bias at the RAMP-CLR complexes – 
Through calculating the change in the ratio of 
log(τ/Ka) between cAMP accumulation and release of 
i(Ca2+), it is possible to determine the extent of 
signaling bias for a ligand (Figure 9 A). In HEK-293 
cells all ligands show cAMP bias over i(Ca2+), except 
for AM2 and CGRP at RAMP2-CLR and RAMP3-
CLR, respectively. In contrast, in HEK-293S cells all 
ligands show clear bias towards cAMP at each 
RAMP-CLR complex. Interestingly, treatment of 
HEK-293 cells with PTX, generates bias profiles 
similar to that observed for HEK-293S cells (Figure 
9). 
Further analysis of these bias factors, relative 
to the cognate ligand at each RAMP-CLR complex 
(Figure 9 B), indicates that only AM2 displays bias 
toward cAMP at the RAMP1- and RAMP3-CLR 
complexes, whilst all other ligands display a 
preference to mobilize i(Ca2+). Again, this is slightly 
different to the bias profile for HEK-293S cells. At 
the RAMP1-CLR complex, AM is biased toward 
i(Ca2+), and AM2 is cAMP biased. For RAMP2-CLR, 
CGRP is biased towards i(Ca2+)  mobilization, whilst 
AM2 is neutral. At RAMP3-CLR all ligands are 
neutral, and display no bias. As before, inhibiting any 
signaling input from Gαi in HEK-293 cells, via PTX 
treatment, generates a relative bias profile comparable 
to that seen in HEK-293S cells. Thus we show that 
not only do RAMPs play a significant role in 
modulating signaling bias, but also cellular G protein 
content can drastically modulate any perceived bias. 
Molecular modeling of CLR and GCGR in 
complex with RAMPs – Our experimental data 
suggests that the RAMPs may perform a critical role 
in modulating G protein coupling and bias. However 
we do not, as yet, have any insight to the mechanism 
by which this may be achieved. To at least partially 
address this issue we turned to the use of molecular 
modelling. We generate models of GCGR in complex 
with RAMP2 and CLR in complex with RAMP1. We 
used the GCGR system since it provides a reference 
system. The interaction between the peptide and the 
ligand is particularly well defined in the homologous 
GLP-1R system through reciprocal mutagenesis and 
photoaffinity labeling (28, 29) and because we have 
shown that the interaction between GCGR and 
RAMP2 affects G protein bias (25). Models taken 
from the last step in the 500 ns trajectory show that in 
both cases, the C-terminal region of the RAMP 
resides in the vicinity of helix 8 (H8), the intracellular 
ends of TM6 and TM7 and the C-terminal region of 
Gαs (Figure 10 A, B). There are differences in the 
orientation of the extracellular domain and the precise 
location of the RAMP transmembrane (TM) helix, 
due to the dynamic nature of the systems, the longer 
‘stalk’ (the region between the ECD and TM1) in 
GCGR and the sequence differences between the 
receptors and between RAMP1 and RAMP2. There 
are no direct interactions between the RAMPs and the 
peptide ligands.  
Analyses of the MD trajectories show that for 
GCGR and CLR, the C-terminal region of the RAMP 
approaches the C-terminal peptide of the G protein 
within the first 100 ns (Figure 10 C). For GCGR the 
primary interaction is with the G protein, but there are 
also interactions with H8. For CLR the first part of the 
tail interacts with the G protein while the tip of the tail 
interacts with H8; in both CLR and GCGR there are 
also interactions with the intracellular end of TM6. 
The interactions are driven by a combination of steric, 
hydrophobic and electrostatic factors. Movies of both 
simulations are provided as supporting information 
(Movie 1 - RAMP2-GCGR-Gαs; Movie 2 – RAMP1-
CLR-Gαs).  
The extracellular end of TM7 of GCGR 
moves inwards under the influence of RAMP2. 
Analysis of distances between the extracellular end of 
TM2 (Cα of residue K205), TM7 (Cα of residue 
G375), the RAMP2 linker (Cα of residue V145) and 
the peptide (Cα of residue Y13) shows that the 
RAMP TM, TM7 and the peptide move as a collective 
unit towards TM2 (Figure 11), indicating a 
mechanism whereby the peptide ligand can influence 
the RAMP, and vice versa even in the absence of a 
direct interaction. 
 
Discussion 
The pharmacology of the CGRP family of 
receptors is relatively well characterized with respect 
to Gαs coupling and the resultant accumulation of 
cAMP (1, 12). Gαq and Gαi coupling to these 
receptors however, is less well characterized. Here we 
report the extension of the use of the S. cerevisiae 
system to investigate signaling bias in the CGRP 
family of receptors. These receptors are obligate 
heterodimers of the GPCR, namely CLR with one of 
three RAMPs. This dimerization adds an increased 
level of complexity to the system. We find that the 
RAMPs influence the G protein coupling in a ligand 
and receptor-dependent manner, in some cases 
radically changing ligand selectivity. 
When GPA1/Gαi coupling in the yeast system 
was compared to coupling to GPA1/Gαs, markedly 
different responses were observed for each ligand. 
Most significantly, at all three receptors, the rank 
order of potency of the ligands was altered, either 
being reversed or differences abolished. Efficacy 
calculations for each ligand in the presence of 
GPA1/Gαi also revealed G protein directed changes in 
the activity of each ligand. AM2 displayed a much 
greater efficacy at the RAMP1-CLR heterodimer than 
AM, and surprisingly CGRP efficacy was greatly 
reduced. These data indicate that the ligands display a 
degree of G protein bias at each receptor and this was 
further supported through the construction of bias 
plots through calculation of ΔΔ(τ/Ka). The data 
contrasts with the established potency profiles for 
Gαs-coupled receptors observed in mammalian cells 
and also yeast. Whilst Gαs is recognized as the main 
signaling pathway activated by CLR-based receptors 
(15), the data illustrate that if Gαi or Gαq activation 
occurs, the conventional agonist potency ratios may 
lead to erroneous conclusions about the nature of the 
receptor. Caution should at least be taken when 
referring to these receptors, since it is clear that CGRP 
will preferentially activate the Gαs-coupled CGRP 
receptor (RAMP1-CLR), but this is not the situation 
when the receptor is coupled to other G proteins. 
Indeed, this trend is observed for all receptors in this 
family, with AM being the preferential ligand for both 
the AM1 (RAMP2-CLR) and AM2 (RAMP3-CLR) 
receptors coupled to Gαs, but not when Gαi coupled. 
To avoid confusion we have, for the most part, 
described these receptors as RAMP1/2/3-CLR in this 
study. A further point that arises from these 
observations is that the reversals in potency ratios that 
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we observe suggest that differences in the ability of 
the peptides to penetrate the yeast cell wall are not a 
factor in contributing to our observations.  
Our data also shed new light on the 
comparative efficacies of CGRP, AM and AM2 at the 
three receptors for Gαs coupling. Typically they have 
been reported to show similar maximum responses, 
although there are issues with incomplete 
concentration-response curves (1). However, there is 
evidence for partial agonism of AM2 in CHO cells 
when RAMP2 is co-expressed with CLR (43). By its 
nature, measurement of efficacy is very sensitive to 
the cell or tissue being studied as well as the 
experimental protocol. In this study, the use of the 
yeast assay enabled us to calculate efficacy and 
potency values for each ligand-receptor combination 
for specific G protein subunits without the 
complication of pathway crosstalk. Our data revealed 
that all ligands have similar efficacies in cells 
expressing the RAMP1-CLR combination coupled to 
GPA1/Gαs. In contrast AM has a significantly 
increased efficacy at the RAMP2-CLR heterodimer.  
The relative potencies of the three peptides at 
the CGRP, AM1 and AM2 receptors that we observe 
in our current studies for Gαs coupling largely agree 
with previous observations (1 for review, 7-9, 43-44), 
Table 2, Figure 12). Importantly when each receptor 
was expressed in S. cerevisiae strains enabling us to 
measure activation of GPA1/Gαs, the rank potency 
order for the peptides fits the pattern observed in 
mammalian cells (Table 1, Figure 9), with the 
exception of CGRP, which displayed an unexpectedly 
high potency at the RAMP3-CLR heterodimer. These 
data indicate that, as with the GLP-1 and glucagon 
receptors, the yeast system is a valid model to study G 
protein coupling to class B GPCRs. The comparable 
pharmacology of the three receptors demonstrates the 
value of the yeast system for assessment of the effect 
of complex formation by GPCRs and could be applied 
not only to dimerization of these receptors with 
RAMPs but also other modifying or downstream 
signaling proteins.  
An important consideration is whether the 
Gαi/Gαq coupling observed in yeast has any relevance 
to mammalian cell systems. The yeast strains only 
express chimeric G proteins (containing the C-
terminal 5 amino acids of the human G protein) which 
have been reported to be less specific when compared 
to equivalent G proteins expressed in mammalian 
cells (22). To establish the extent of Gαi coupling in 
HEK-293 cells, we investigated cAMP production 
before and after PTX treatment; the greater the 
enhancement of cAMP production following toxin 
addition, the greater the extent of Gαi coupling that 
the toxin inactivates. When compared with the 
coupling seen in yeast to GPA1/Gαi, whilst the 
correlation is not exact, there is at least a measure of 
agreement between the HEK-293 and yeast data, 
which suggests the latter, may be a guide as to what 
could be seen in mammalian cells, given the 
appropriate conditions. Comparing the relative bias 
plots for yeast and HEK-293 cells in Figures 7 and 9 
further emphasizes this; the pattern shown for the two 
systems is broadly similar. As the effects of RAMPs 
on GPCR pharmacology are known to be sensitive to 
the cell line background (37, 42) and significant 
heterogeneity in PTX-sensitivity of CGRP has been 
previously reported (20, 45), it would perhaps be 
surprising if the HEK-293 cells were a perfect match 
to yeast. Indeed, as we have shown (Figure 6), in 
terms of the expression levels of Gαi subunits, two 
similar HEK-293 cell lines are, in fact, very different: 
HEK-239S cells appear to have a reduced level of Gαi 
expression compared to HEK-293 cells. When 
combined with our observation for the PTX-
sensitivity of the CLR response in HEK-293S cell 
lines, it becomes apparent that we need to carefully 
consider the G protein-content of cell lines that we 
utilize when we are investigating G protein-mediated 
signaling bias.  
 Our results demonstrate that the CGRP family 
of receptors can couple to Gαs, Gαi and Gαq subunits. 
Further, using the yeast system we observed a ligand-
dependent G protein coupling bias with each receptor 
highlighting the ability of the yeast platform to 
uncover potential G protein bias for other GPCRs. 
Importantly, this is at least partially, transferred into 
mammalian cells and provides an excellent starting 
point for subsequent investigations, into both the 
extent to which this bias occurs in native mammalian 
cells and the molecular basis for the phenomenon. 
Any consideration of the physiological significance of 
G protein promiscuity needs to consider the cellular 
background in which the CLR/RAMP receptor is 
expressed; we observe significant differences between 
our three cell hosts that depend, at least partly, on the 
G proteins they express (Figure 13). Indeed it is worth 
highlighting that, as a direct consequence of the 
reduced overall Gαi content in HEK-293S cells, all 3 
ligands at the CGRP family of receptors display bias 
towards cAMP accumulation over i(Ca2+) release 
(Figure 9). Coupling to Gαi (or possibly Gαo) may be 
particularly relevant in neuronal and other electrically 
excitable cells where many (18-19) of the effects of 
PTX on CGRP have been observed (reviewed in 15). 
In neuronal and other cells, the direct Gαi/Gαo effects 
on ion channels may also be particularly significant. 
For example, there is the potential for a complex 
interplay between neuronally released CGRP and the 
AM or AM2 peptides released locally through cross-
talk between all three CLR-based receptors, with the 
potential of the Gαi coupling to naturally limit 
excitation produced via Gαs.  
 The role of Gαq/11 coupling in mediating 
responses to CGRP, AM and AM2 has not been well-
investigated; the few relevant studies have examined 
activation of protein kinase C or release of calcium 
from internal stores rather than directly studying 
Gαq/11. For CGRP, a further complication is that it can 
also activate the amylin-1 receptor with high affinity 
(46) so it is not always clear that the observed effects 
are mediated via CLR. However, in HEK293 cells, 
alveolar epithelial cells, dorsal root ganglia and 
trigeminal ganglia, there is evidence for either release 
of intracellular calcium or activation of PKC 
alongside PKA activation (15). A similar pattern has 
been seen for AM in bovine aortic endothelial cells 
(47). Whilst evidence from PKA inhibitors such as 
H89 suggests that cAMP is the primary second 
messenger mediating many effects of CGRP (48), 
there is the potential for spatial and temporal 
modulation of this primary signal via i(Ca2+), a 
possibility that remains to be explored. 
By utilizing Molecular models of two diverse 
class B GPCR systems, namely RAMP1-CLR-CGRP 
and RAMP2-GCGR-glucagon systems we have 
gained insights into signaling bias. We believe the 
simulations reported here are the first molecular 
dynamics simulations on RAMP-GPCR heterodimers. 
The interaction of the RAMP TM helix with 
TM6/TM7 is supported by both docking experiments 
on CLR (27) and by studies on the secretin-GLP-1 
chimeric receptor (49); this interaction remains stable 
throughout both 500 ns simulations of the active 
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receptors, with the RAMP retaining a straight helix 
through both simulations, despite the presence of 
proline(s). The interaction is primarily with TM7 and 
the N-terminal end of TM6. This provides some 
evidence that GCGR and CLR may interact with 
RAMP in a similar way. Despite the persistence and 
stability of the TM interactions, the C-terminus is 
quite flexible, sampling a wide region of space in both 
simulations. RAMP2 interacts primarily with the C-
terminus of Gαs while RAMP1 interacted primarily 
with H8 but also made contacts with TM6 and most 
importantly Gαs. These simulations therefore indicate 
that the RAMP could affect the bias shown in G 
protein coupling by CLR either by direct interaction, 
and, or, allosterically by altering the orientation of 
TM6 and TM7 or H8. These simulations were carried 
out on a model of the active receptor in complex with 
a C-terminal fragment of Gαs (R374 to L394). The C-
terminal helix of Gαs sits above the face of the G 
protein. Models of RAMP2-GCGR in complex with 
the G protein heterotrimer indicate that the RAMP 
could also interact directly with residues around G353 
of Gαs (results not shown).  
In addition, allosteric effects of the RAMP 
linker may alter the extracellular face of the receptor 
(as seen in CLR with RAMP2 and RAMP3 (27)) and 
these effects could be transmitted to the intracellular 
end of the helix. In our simulations we see some 
evidence for the top of TM7 moving in toward the 
TM bundle under pressure of the RAMP (Figure 11) 
as part of a collective unit comprised of TM7, the 
peptide and the RAMP TM. This concerted movement 
provides a possible mechanism whereby the influence 
of the ligand can be conveyed to the RAMP and 
thereby affect the bias via interactions of the C-
terminus of the RAMP. The inward movement of the 
extracellular end of TM7 has been explicitly linked to 
activation (50), but movement of TM6 and / or H8 
under the influence of the RAMP may also affect bias 
and activation. Thus we suggest that RAMPs have the 
potential to interact allosterically with not only the 
GPCR but also the bound G protein. This leads to the 
possibility that, upon ligand binding the RAMPs 
contribute to the G protein bias. In order to confirm 
this we aim to extend this project to investigate all 
ligand-RAMP-CLR-G protein complexes, to further 
elucidate the roles RAMPs play in modulating G 
protein coupling and bias at the CGRP family of 
receptors. 
Finally, we suggest that this study has broader 
implications. Our results shown here are similar to 
those described for the GCGR (25) in that RAMPs 
alter the ability of peptides to stimulate different G 
proteins. However, as we have shown significant 
pharmacological differences can be observed in 
differing recombinant cell lines, and expression 
systems. These differences can be explained through 
several factors; firstly these systems rely upon over 
expression of the receptor and chaperone proteins 
under study, and secondly upon cellular content of 
further downstream signaling proteins, such as G 
proteins. It is therefor important that findings in 
systems such as those explained here are further 
validated. This would be best achieved in cell lines 
endogenously expressing the GPCR, and RAMP, of 
interest. This is thus something we aim to undertake 
as a follow up to the work presented here, for 
CLR/RAMP complexes. It is clear that there is a 
complex interplay between the ligand, the RAMP and 
the CLR that alters G protein activation for these 
receptors. Further, our data adds to the growing 
wealth of literature suggesting that many ligands for 
class B GPCRs display either Gαs or Gαi signaling 
preference. To date this ligand-engendered bias has 
been observed for receptors binding corticotropin-
releasing factor, urocortin 1, GLP-1 and glucagon 
(24-25, 51). In this study, the yeast growth assay 
system was able to provide a valuable indication of 
the potential of the CGRP family of receptors to 
couple to either Gαs or Gαi when stimulated by 
CGRP, AM or AM2, allowing us to uncover novel G 
protein signaling preferences for each ligand. We can 
therefore conclude that this system is a good platform 
with which to explore the effect of RAMP 
dimerization to other members of the class B GPCRs.  
 
Methods 
Materials - Human (h) αCGRP, hAM and 
hAM2 (1-47) were purchased from Bachem 
(Bubendorf, Switzerland) and made to 1 mM stocks in 
water containing 1% BSA. Yeast nitrogen base and 
yeast extract were purchased from Difco (Franklin 
Lakes, NJ). Flurorescein-Di-β-D-glucopyranoside 
(FDGlu) was purchased from Invitrogen (Paisley, 
UK). Forskolin was from Tocris Bioscience 
(Wiltshire, UK), YM-254890 was supplied by alpha 
laboratories (Hampshire, UK). Both ALPHAScreen 
and LANCE® cAMP detection assay kit and all 
reagents were from PerkinElmer (Boston, MA, USA).  
Expression Constructs - To enable expression 
of the human CLR we used either a previously 
described (25) myc-tagged cDNA construct provided 
by Dr Michel Bouvier (University of Montreal, 
Canada) or a human CLR with an N-terminal 
haemaglutinin (HA) epitope tag. All human FLAG-
tagged RAMPs were used as described previously 
(37).  
Yeast strain construction and assay - General 
yeast procedures were performed as described 
previously (22, 24). The human CLR was introduced 
into yeast cells under the control of the PGK promoter 
using a plasmid containing ura3 (pDT-PGK). The 
three human RAMPs were introduced into yeast under 
the control of the GAPDH promoter using plasmids 
containing leu2 (p425-GPD) (25). S. cerevisiae dual 
reporter strains expressing chimeras of the yeast 
GPA1, 1-467, (GPA1/Gα) with the five C-terminal 
amino acids of 11 human G proteins representing Gαs, 
Gα16, Gαq, Gαo, Gαi1/2, Gαi3, Gαz, Gα12, Gα13, and Gα14 
(MMY84-MMY93) were used in this study (52). The 
human CLR and RAMPs were transformed into yeast 
cells (at a ratio of 1:1 to enable equal expression) 
using the lithium acetate/single-stranded 
DNA/polyethylene glycol method as previously 
described (53). Positive transformants were selected 
and maintained on synthetic dropout (SD) media 
lacking both uracil and leucine (SD-URA-LEU). 
Receptor signaling was measured using the yeast 
growth assay as described previously (24). Cell 
growth was initially performed in SD-URA-LEU 
media at 30oC to select cells only expressing both 
plasmids. Cells were then cultured to remove basal 
activity in SD-URA-LEU-HIS media overnight at 
30oC and assayed using media supplemented with 
FDGlu. Fluorescein signal was detected as an increase 
in fluorescence (excitation wavelength = 485%nm, 
emission wavelength = 535%nm) as a measure of 
growth. Different concentrations of ligand (0.01 nM - 
100 µM) were assayed using 96-well plates and 
fluorescence detected using a TECAN Infinite M200 
microplate reader (TECAN Ultra Evolution, Reading, 
UK) or a Mithras LB940 microplate reader (Berthold 
Technologies, Harpenden, UK) for 20%h. Positive 
isolates were selected upon their ability to grow in 
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SD-URA-LEU-HIS media, above basal, when 
stimulated with 10 µM CGRP or AM as appropriate 
for the RAMP-CLR complex being studied. Chimeric 
strains were deemed not to functionally couple when 
n > 16 isolates had been assayed and none showed 
growth above basal levels. In this study functional 
couplings were only observed for MMY84, MMY86 
and MMY88 representing Gαs, Gαi1/2 and Gαq 
respectively.  
Mammalian Cell Culture and Transfection - 
HEK-293 cells, provided by Dr Jügen Müller 
(University of Aston), were cultured in Dulbecco’s 
Modified Eagle Medium (DMEM) supplemented with 
10% heat inactivated fetal bovine serum (FBS) and 
kept in a 37°C, humidified 95% air, 5% CO2 
incubator. HEK-293S cells (a gift from AstraZeneca) 
were cultured in DMEM supplemented with 8% heat 
inactivated FBS and kept in a 37°C humidified 95% 
air, 5% CO2 incubator. HEK-293 cells were 
transfected with Fugene 6 (Roche) in accordance with 
the manufacturer’s instructions using a 1:3 (w:v) 
DNA:Fugene ratio and a 1:1 ratio of RAMP to CLR. 
HEK-293S cells were seeded into 96 well poly-D-
lysine coated plates at a density of 15,000 cells per 
well (determined using a Countess Counter™, 
Invitrogen) one day prior to transfection. HEK-293S 
cells were transiently transfected as described 
previously (38) using a 1:1 ratio of RAMP to CLR. 
Transfected cell lines were grown for 24-48 h prior to 
assaying. Where appropriate, PTX (200 ng/ml) was 
added to ADP-ribosylate Gαi for 16 h prior to 
assaying, thereby uncoupling receptor-mediated Gαi-
dependent inhibition of cAMP production. !
cAMP accumulation assays -  Transfected 
HEK-293 cells were washed in PBS, resuspended in 
stimulation buffer (PBS containing 0.1% BSA and 0.5 
mM IBMX) and seeded at 2000 cells per well in 384-
well white Optiplates. Ligands were added in the 
range of 1 pM to 1 mM and cAMP accumulation was 
measured after 30 min stimulation using LANCE® 
cAMP Detection Kit (PerkinElmer, MA, USA). We 
have previously found 30 min stimulation to be the 
optimum time for assaying cAMP accumulation for 
family B GPCRs (24, 25). Plates were read using a 
Mithras LB 940 multimode microplate reader 
(Berthold technologies, Germany). HEK-293S cells 
were assayed for cAMP accumulation as described 
(54). Values were converted to concentration using a 
cAMP standard curve performed in parallel.  
Calcium mobilization assays - Transfected 
HEK-293 cells were grown to confluence in black, 
clear bottomed, 96 well plates. On the day of assay 
cells were washed with calcium free HBSS and 
incubated for 1 h, at room temperature, in the 
presence of 10 µM Fluo-4/AM (Invitrogen, Paisely, 
UK) containing 2.5 mM probenecid. Cells were then 
washed, followed by addition of 100 µl Ca2+ free 
HBSS. Ligands were robotically added using a 
Mithras LB 940 multimode microplate reader, in the 
range of 10 pM to 1 µM, and fluorescence determined 
immediately post-injection, with an excitation 
wavelength set to 485 nm and an emission wavelength 
set to 535 nm. Recordings were obtained every 0.5 s 
for 120 s. Peak magnitude was calculated using five-
point smoothing, followed by correction against 
background fluorescence. The peak was used to 
generate concentration-response curves and 
normalized relative to 10 µM ionomycin. In order to 
determine the roles played by Gαq/11 in i(Ca2+) 
mobilization, cells were pretreated (for 30 mins) with 
100 nM YM-254890 to inhibit Gαq/11 signaling (42). 
Reverse-transcriptase-polymerase chain 
reaction (RT-PCR) - RNA was extracted from HEK-
293 and HEK-293S cells using RNAqueous 4 
Polymerase chain reaction (PCR) kit (ThermoFisher, 
Paisely, UK) as per the manufacturers protocol. All 
RNA samples were treated with DNaseI to remove 
contaminating genomic DNA. Reverse transcription 
was performed using a QuantiTect reverse 
transcription kit (Qiagen, Manchester, UK). The PCR 
amplification was performed as described previously 
(55) using gene-specific primers to human Gα 
subunits; Gαs; forward – 
CGACGACACTCCCGTCAAC, reverse – 
CCCGGAGAGGGTACTTTTCCT (PrimerBank ID – 
3297877a1, (55)), Gαi1; forward – 
TTAGGGCTATGGGGAGGTTGA, reverse – 
GGTACTCTCGGGATCTGTTGAAA (PrimerBank 
ID 156071490c1, (55)), Gαi2; forward – 
TACCGGGCGGTTGTCTACA, reverse – 
GGGTCGGCAAAGTCGATCTG (PrimerBank ID – 
261878574c1, (55)), Gαi3; forward – 
ATCGACCGCAACTTACGGG, reverse 
AGTCAATCTTTAGCCGTCCCA (PrimerBank ID –  
169646784c1, (55)), Gαq; forward – 
TGGGTCAGGATACTCTGATGAAG, reverse – 
TGTGCATGAGCCTTATTGTGC (PrimerBank ID – 
312176363c1, (55)), Gα11; forward – 
GGCTTCACCAAGCTCGTCTAC, reverse – 
CACTGACGTACTGATGCTCG (PrimerBank ID – 
115511048c1, (55)), Gαz; forward – 
GGTCCCGGAGAATTGACCG, reverse – 
ATGAGGGGCTTGTACTCCTTG (PrimerBank ID –  
45580725c1, (55)), Gα0; forward – 
GGAGCAAGGCGATTGAGAAAA, reverse – 
GGCTTGTACTGTTTCACGTCT (PrimerBank ID –  
162461737c1, (55)), Gα12; forward – 
CCGCGAGTTCGACCAGAAG, reverse – 
TGATGCCAGAATCCCTCCAGA (PrimerBank ID –  
42476110c1, (55)), Gα13; forward – 
CAGCAACGCAAGTCCAAGGA, reverse – 
CCAGCACCCTCATACCTTTGA (PrimerBank ID –  
215820623c1, (55)), Gα14; forward – 
GAGCGATGGACACGCTAAGG, reverse – 
TCCTGTCGTAACACTCCTGGA (PrimerBank ID –  
222418795c1, (55)), Gα15; forward – 
CCAGGACCCCTATAAAGTGACC, reverse – 
GCTGAATCGAGCAGGTGGAAT (PrimerBank ID 
156104882c1, (55)), glyceraldehyde 3-phosphate 
dehydrogenase (GAPDH); forward – 
AATGGGCAGCCGTTAGGAAA, reverse – 
GCGCCCAATACGACCAAATC. All products were 
resolved on a 2% agarose gel and imaged using a 
G:Box iChemi gel documentation system utilizing 
Gene Tool analysis software (Syngene, Cambridge, 
UK), densitometry was performed using Gene Tool.  
Molecular Modelling – Models of the GCGR 
in complex with RAMP2 and CLR in complex with 
RAMP1 were based on the previously reported 
models of GLP-1R in complex with GLP-1 and CLR 
in complex with RAMP2/3 respectively (27-29); these 
models were built using modeler 9.16 (57) from the 
GCGR and CRFR X-ray structures of the TM domain 
(58, 59), the X-ray structures of the extracellular 
domain (ECD) (60, 61) and NMR structures of 
closely related peptides (62, 63). The helical region of 
the CGRP peptide was structurally aligned to the 
corresponding region in GLP-1 based on the sequence 
alignment (27) because the position of the GLP1 helix 
within GLP-1R is well defined by experimentation; 
the initial models are available as supporting 
information. The RAMP-GPCR complexes were 
placed in a hydrated POPC membrane using the 
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CHARMM GUI (64) to generate a system containing 
20,482 and 28,013 TIP3P water molecules (65), as 
well as 183 and 243 lipid molecules for the RAMP2-
GCGR and RAMP1-CLR heterodimers, respectively. 
The histidine protonation was determined using the 
PDB2PQR server (66). The AMBERSP99 force field 
parameters for the protein (67), and the lipid14 force 
field parameters for POPC (68, 69) were added using 
ambertools (70). Molecular dynamics simulations 
were run for 500 ns at 298 K using ACEMD (71).  
Data Analysis - Data analysis for cAMP 
assays was performed in GraphPad Prism 6.0f (San 
Diego, CA, USA). Data were fitted to obtain 
concentration–response curves using either the three-
parameter logistic equation (for pEC50 values), or the 
operational model for partial agonism (34) to obtain 
values of efficacy (log τ) and the equilibrium 
dissociation constant (log kA). These values were then 
used to quantify signaling bias as change in log (τ/kA) 
relative to the natural cognate ligand for the respective 
receptor (41). We denoted these as CGRP for CLR 
with RAMP1, and AM for CLR with either RAMP2 
or RAMP3. Statistical differences were analyzed 
using one-way ANOVA or Student’s t-test as 
appropriate with post-hoc Bonferroni's or Dunnett's 
multiple comparisons, a probability of (p) < 0.05 was 
considered significant. Correlations between pEC50 
values, for cAMP assays, of HEK-293 and HEK-293S 
cells were assessed by scatter plot and Pearson’s 
correlation coefficient (r). For the RT-PCR, 
normalization to the internal standard GAPDH was 
performed to reduce variance and enable comparison 
between different cell lines. In order to quantitate the 
ligand-dependent response in the yeast system, a 
strain lacking GPA1 (MMY11), grown in rich media, 
was used as a standard (72). As GPA1 is not present 
in this strain, the Gβγ subunits are unregulated and 
free to signal, allowing us to determine the maximal 
response of our system. Emax values are reported as a 
percentage of this maximum response and statistical 
analysis has been performed on this data.  For the 
mammalian cell based assays, data analysis was 
carried out as for the yeast curves. To account for the 
day-to-day variation experienced from transient 
transfections we have used the maximal level of 
cAMP accumulation from cells in response to 100 µM 
forskolin stimulation as our reference, and 10 µM 
ionomycin for i(Ca2+) assays. Emax values from these 
curves are reported as a percentage of these controls 
and all statistical analysis has been performed on this 
data. Where appropriate the operational model for 
partial agonism (34) was used to obtain values of 
efficacy (log τ) and equilibrium disassociation 
constant (log Ka). In both cases, this normalization 
removes the variation due to differences in 
transfection or transformation but retains the variance 
for control values. The means of individual 
experiments were combined to generate the curves 
shown. 
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Figure legends 
 
Figure 1. Functional expression of CLR co-transformed with all three RAMPs in yeast cells. Dose response 
curves to CGRP, AM and AM2 were constructed in yeast strains containing the GPA1/Gαs chimera and 
expressing CLR with (A), RAMP1 (n = 6) (B), RAMP2 (n = 7) and (C), RAMP3 (n = 8). Reporter gene activity 
was determined following 20 h stimulation with each ligand. Data are expressed as percentage of the maximum 
response observed in a yeast strain MMY11 (lacking GPA1) and are means ± SEM of n individual data sets. (D) 
Bar chart showing the efficacy of each ligand for each RAMP-CLR combination as determined via application 
of the operational model of receptor agonism ((34); Table 1). Data were determined as statistically different from 
the cognate ligand for each receptor (*, p < 0.05, **, p < 0.01, ***, p < 0.001) using a one-way ANOVA with 
Bonferroni’s post-test.  
 
Figure 2. Expression of CLR in combination with each RAMP generates functional Gαs-coupled receptors 
in HEK-293 cells. cAMP accumulation was determined in HEK-293 cells transiently transfected with the CLR 
and (A), RAMP1 (n = 11) (B), RAMP2 (n = 8) and (C), RAMP3 (n = 9)  following 30 min stimulation with 
CGRP, AM and AM2. Data are expressed as percentage maximal cAMP production, determined using 100 µM 
forskolin stimulation and are means ± SEM of n individual data sets. (D) Bar chart showing the efficacy of each 
ligand for each RAMP-CLR combination as determined via application of the operational model of receptor 
agonism (34). Data were determined as statistically different from the cognate ligand for each receptor (*, p < 
0.05, **, p < 0.01) using a one-way ANOVA with Bonferroni’s post-test. 
 
Figure 3. Co-transformation of CLR with all three RAMPs in yeast cells generates receptors that 
functionally couple to the Gαi chimera. Dose response curves to CGRP, AM and AM2 were constructed in 
yeast strains containing the GPA1/Gαi chimera and expressing CLR with (A), RAMP1 (n = 6) (B), RAMP2 (n = 
6) and (C), RAMP3 (n = 7). Reporter gene activity was determined following 20 h stimulation. All data are 
expressed as percentage of the maximum response observed in a yeast strain MMY11 (lacking GPA1) and are 
means ± SEM of n individual data sets. (D) Bar chart showing the efficacy of each ligand for each RAMP-CLR 
combination as determined via application of the operational model of receptor agonism ((34); Table 1). Data 
were determined as statistically different from the cognate ligand for each receptor (*, p < 0.05, **, p < 0.01, 
***, p < 0.001, ****, p < 0.0001) using a one-way ANOVA with Bonferroni’s post-test. 
!
Figure 4. CLR in combination with each RAMP generates receptors that display PTX-sensitive effects in 
response to ligand stimulation. cAMP accumulation was determined in the presence (treated) and absence 
(untreated) of PTX, from HEK-293 cells transiently transfected with CLR and (A), RAMP1 (n = 6) (B), RAMP2 
(n = 5) and (C), RAMP3 (n = 5). Cells were stimulated for 30 min with CGRP, AM and AM2; data are 
expressed as percentage of the maximal cAMP production as determined using 100 µM forskolin stimulation in 
presence of PTX and are means ± SEM of n individual data sets.!
!
Figure 5. RAMP-CLR responses appear PTX-insensitive when assayed using HEK-293S cells. cAMP 
accumulation was determined in the presence (treated) and absence (untreated) of PTX, from HEK-293S cells 
transiently transfected with CLR and (A), RAMP1 (n = 5) (B), RAMP2 (n = 5) and (C), RAMP3 (n = 5). Cells 
were stimulated for 30 min with CGRP, AM and AM2; data are expressed as percentage of the maximal cAMP 
production as determined using 100 µM forskolin stimulation in presence of PTX and are means ± SEM of n 
individual data sets.  
 
Figure 6. Reduced Gαi expression in HEK-293S cell lines leads to PTX-sensitive. (A) Expression profiles of 
Gα genes were assessed in HEK-293 and HEK-293S cells. RNA was extracted from cells and treated with 
DNase1 to remove genomic DNA contamination. Gα gene expression was examined by RT-PCR using gene-
specific primers. The * indicates a lack of detectable transcript for Gαi2. The band shown is a non-specific 
product as confirmed by DNA sequencing. (B) Semi-quantitative expression (relative to GAPDH) for the Gα 
genes from (A) (n = 4). Statistical difference between HEK-293 and HEK-293S cells was determined using 
Student’s t-test where *, p < 0.05, **, p < 0.01. (C) Correlation of log agonist potencies (± SEM) for CGRP, AM 
and AM2 at RAMP-CLR combinations expressed in HEK-293S (Table 4) cells and either HEK-293 cells with 
(red symbol) or without (blue symbol) pre-treatment with PTX (Table 3) was analyzed by a scatter plot and 
Pearson’s correlation coefficients (r) were calculated. A significant correlation was observed only between HEK-
293S cells and HEK-293 cells pre-treated with PTX.  
 
Figure 7. Functional coupling of CLR co-transformed with all three RAMPs to the Gαq chimera. Dose 
response curves to CGRP, AM and AM2 were constructed in yeast strains containing the GPA1/Gαq chimera 
and expressing CLR with (A), RAMP1 (n = 7) (B), RAMP2 (n = 6) and (C), RAMP3 (n = 7). Reporter gene 
activity was determined following 24 h stimulation. All data are expressed as percentage of the maximum 
response observed in a yeast strain MMY11 and are means ± SEM of n individual data sets. (D) Bar chart 
showing the efficacy of each ligand for each RAMP-CLR combination at the Gαq chimera determined via 
application of the operational model of receptor agonism ((34); Table 1). Data were determined as statistically 
different from the cognate ligand for each receptor (*, p < 0.05, **, p < 0.01, ***, p < 0.001) using a one-way 
ANOVA with Bonferroni’s post-test. (E) Signaling bias plots were calculated as ΔΔ(τ/Ka) values on a 
logarithmic scale for each ligand and for each chimera G protein for the three individual RAMP-CLR 
complexes. Determination of values requires normalization to a reference ligand (CGRP for RAMP1-CLR and 
AM for CLR with RAMP2 or RAMP3) and a reference pathway (in all cases GPA1/Gαs).  
 
Figure 8. CLR in combination with each RAMP generates receptors that mobilize i(Ca2+) release when 
expressed in HEK-293 cells. i(Ca2+) mobilization was determined from HEK-293 cells transiently transfected 
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with CLR and (A), RAMP1 (n = 5) (B), RAMP2 (n = 5) and (C), RAMP3 (n = 5). Cells were stimulated for 2 
min with CGRP, AM and AM2 and data are expressed as percentage of the maximal i(Ca2+) release as 
determined using 10 µM ionomycin. To determine the contribution made by different G proteins to the i(Ca2+) 
response, cells were pre-incubated with either PTX (to inhibit Gαi) or YM-254890 (a selective Gαq inhibitor). 
All values are means ± SEM of n individual data sets.  
 
Figure 9. Quantification of biased agonism at the three RAMP-CLR complexes. (A) Normalized 
transduction coefficients, Δlog (τ/Ka), for cAMP accumulation and i(Ca2+) mobilization obtained for the three 
RAMP-CLR complexes upon stimulated with CGRP, AM or AM2 in untreated HEK-293 cells, HEK-293 cells 
treated with PTX and HEK-293S cells. (B) Relative bias factors, ΔΔ(τ/Ka), for cAMP accumulation and i(Ca2+)  
mobilization for the three individual RAMP-CLR complexes upon stimulated with CGRP, AM or AM2 in 
untreated HEK-293 cells, HEK-293 cells treated with PTX and HEK-293S cells. Determination of values 
requires normalization to a reference ligand (CGRP for RAMP1-CLR and AM for CLR with RAMP2 or 
RAMP3) and a reference pathway (in all cases cAMP accumulation). 
 
Figure 10. Class B GPCR:RAMP Heterodimeric Models and Molecular Dynamics Simulations. Molecular 
models and dynamic simulation suggest that the C-terminal tail of RAMP1/2 (olive/yellow) when in complex 
with either (A) GCGR (blue) or (B) CLR (teal) makes a direct interaction with the bound C-terminal of Gαs 
(green) and or helix 8. The glucagon peptide agonist is shown in magenta and CGRP is shown in purple. C) The 
RAMP2 C-terminus approaches toward Gαs (red arrow) during a molecular dynamics simulations of an active 
GCGR-RAMP2-glucagon complex. RAMP2 is yellow, Gαs is green, and the GCGR is coloured according to 
time progression, from red (0 ns) to blue (500 ns). 
!
Figure 11. The peptide agonist, the GPCR TM7 and the RAMP TM helix move as a collective unit during 
molecular dynamics simulations. (A) Schematic diagram of the distances between the members of the 
collective unit and TM2. Top arrow bars indicate the following distances in order: RAMP2-TM2 (green), TM7-
TM2 (cyan), peptide-TM2 (orange). Bottom arrow bars indicate the distances within the members of the 
collective unit in order: RAMP2-peptide (purple), RAMP-TM7 (black), TM7-peptide (red). (B) Distances from 
each of the collective unit components (RAMP TM, TM7 and glucagon agonist) to TM2 (order as above); these 
distances decrease in a similar manner, reflecting their concerted movement. (C) Distances between each of the 
collective unit components (RAMP, TM7 and glucagon agonist) (order as above); these distances are relatively 
constant, reflecting their movement as a collective unit. 
 
Figure 12. Agonist potency ratios for CGRP, AM and AM2 at the CLR in combination with each RAMP. 
Log potency ratios (as measured by accumulation of intracellular cAMP) are defined as Log [EC50 AM2 ÷ EC50 
Agonist]. Data taken from Hong et al. (1) supplemented with references (43, 44). HEK-293 and HEK-293S cell 
data from the current study are shown in red and blue, yeast Gαs coupling is shown in green. 
 
Figure 13. A working model of biased-agonism at the different RAMP-CLR complexes. The individual 
RAMP-CLR complexes can bind the agonists CGRP (red), AM (Green) and AM2 (Blue) to activate different 
downstream chimeric GPA1/Gα subunits (in yeast) or promote increases in intracellular cAMP and/or mobilize 
release of i(Ca2+) (in HEK-293/HEK-293S cells). The thickness of lines indicates the bias that each agonist 
displays for either the chimeric G protein or the specific downstream signaling cascade.  The yeast system 
enables comparison of different individual G proteins (Gαs, Gαi1/2 and Gαq) while mammalian cells investigate 
cAMP accumulation (± PTX) and elevation of i(Ca2+).  
!
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Figure 5 –HEK PTX (Harriet) 
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Figure 5 – EK PTX ( arriet) 
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Figure 5 –HEK PTX (Ha riet) 
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Figure 5 –  T  ( arriet) 
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Figure 5 –HEK PTX (Harriet) 
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Table 1: Summary table of pharmacological parameters for various ligands upon expression of the CLR with each RAMP in yeast strains containing the 
GPA1/Gαs GPA1/Gαi or the GPA1/Gαq chimera. 
 
Data are the mean ± SEM of n individual data sets (in parentheses).  
a The negative logarithm of the agonist concentration required to produce a half-maximal response. 
b The maximal response to the ligand expressed as a percentage of that obtained from a yeast strain (MMY11) lacking GPA1. 
c The negative logarithm of the equilibrium disassociation constant for each ligand generated through use of the operational model of agonism (34). 
d τ is the coupling efficiency parameter of each ligand. 
Statistical significance compared to the cognate ligand (*, p < 0.05, **, p < 0.01, ***, p < 0.001, ****, p < 0.0001) for each receptor heterodimer (CGRP 
for RAMP1 + CLR; AM for CLR with either RAMP2 or RAMP3) was determined by one-way ANOVA with Dunnett’s post-test. 
 
   GPA1/Gαs   
 RAMP1-CLR  RAMP2-CLR  RAMP3-CLR 
CGRP AM AM2 CGRP AM AM2 CGRP AM AM2 
pEC50a   9.35±0.2*   8.80±0.4***   7.22±0.3***   7.60±0.3*   8.82±0.3*   8.05±0.3*   8.24±0.2   8.15±0.4   8.85±0.3 
Emaxb 27.10±1.6* 20.39±2.8*** 20.65±1.1*** 30.34±4.1 37.46±3.5 19.90±2.5*** 30.17±2.7 25.51±3.6 22.80±2.3 
pKac   9.22±0.2*   8.81±0.3***   7.31±0.3***   7.70±0.3*   8.77±0.3   8.10±0.3   8.30±0.3   8.10±0.3   8.61±0.4 
logτd  -0.43±0.04  -0.59±0.07* -0.61±0.08  -0.38±0.08*  -0.23±0.06  -0.61±0.06**  -0.42±0.08  -0.51±0.08  -0.57±0.08 
n 6 6 6 7 7 7 8 8 8 
   GPA1/Gαi   
 RAMP1-CLR  RAMP2-CLR  RAMP3-CLR 
CGRP AM AM2 CGRP AM AM2 CGRP AM AM2 
pEC50a   8.26±0.5   8.38±0.3 *  8.57±0.2**   8.89±0.2**   7.91±0.2**   8.42±0.5**   8.52±0.2   7.89±0.8   8.49±0.2 
Emaxb 19.80±3.0* 34.20±3.7***  41.5±3.3**** 24.43±1.7* 24.49±2.0* 15.71±2.5* 22.60±1.8* 26.71±1.8* 15.71±2.1* 
pKac   8.40±0.5   8.20±0.3**  8.24±0.2   8.64±0.2   7.75±0.2   8.30±0.5   8.37±0.2   8.00±0.2   8.30±0.3 
logτd  -0.70±0.1** -0.33±0.07** -0.18±0.1*** -0.50±0.04** -0.51±0.05*  -0.89±0.1**  -0.56±0.06* -0.50±0.05* -0.78±0.07* 
n 6 6 6 6 6 6 7 7 7 
   GPA1/Gαq   
 RAMP1-CLR  RAMP2-CLR  RAMP3-CLR 
CGRP AM AM2 CGRP AM AM2 CGRP AM AM2 
pEC50a   7.53±0.1   7.26±0.2   7.99±0.2   7.14±0.2   7.93±0.2   9.22±0.4*   6.19±0.5*   7.83±0.2   6.76±0.25 
Emaxb 26.50±1.2 14.08±1.2**** 16.73±1.1**** 27.74±2.3 29.03±2.6 11.33±1.3****   20.7±4.2 25.56±2.0 32.11±3.7 
pKac 27.40±0.1  7.19±0.2  7.91±0.03   7.01±0.2   7.78±0.2   9.16±0.4*   6.10±0.6*   7.71±0.2   6.60±0.3 
logτd -0.46±0.03 -0.79±0.04*** -0.70±0.04***  -0.42±0.05  -0.39±0.05 -0.88±0.08***  -0.63±0.2 -0.48±0.05  -0.34±0.1 
n 7 7 7 6 6 6 6 6 6 
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Table 2: Potency (pEC50), affinity (pKa) and coupling efficacy (log τ) values for cAMP production at the CLR co-expressed with each RAMP and stimulated with 
various agonists measured in HEK-293 cells. 
 
 
 
 
 
 
 
 
 
 
 
Data are the mean ± SEM of n individual data sets. 
a The negative logarithm of the agonist concentration required to produce a half-maximal response. 
b The maximal response to the ligand expressed as a percentage of the maximal cAMP production as determined using 100 µM forskolin stimulation. 
c The negative logarithm of the equilibrium disassociation constant for each ligand generated through use of the operational model of agonism (34). 
d τ is the coupling efficiency parameter of each ligand. 
Statistical significance compared to the cognate ligand (*, p < 0.05, **, p < 0.01, ***, p < 0.001, ****, p < 0.0001) for each receptor heterodimer (CGRP for 
RAMP1-CLR; AM for CLR with either RAMP2 or RAMP3) was determined by one-way ANOVA with Dunnett’s post-test. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  RAMP1-CLR  RAMP2-CLR  RAMP3-CLR 
CGRP AM AM2 CGRP AM AM2 CGRP AM AM2 
pEC50a   9.81±0.20  7.92±0.19**  7.93±0.24**   8.97±0.24*** 10.35±0.13   7.48±0.23***   7.75±0.3**   8.86±0.14  9.14±0.22** 
Emaxb   45.0±2.2  45.2±3.7  43.6±4.2**   37.2±2.4***   55.0±1.7   34.1±4.0**   22.3±2.1**   32.1±1.6   21.9±1.7** 
pKac   9.60±0.18  7.64±0.28**  7.76±0.20**   8.71±0.2**   9.95±0.23   7.16±0.24**   7.64±0.26**   8.50±0.19   9.00±0.18** 
logτd -0.08±0.04 -0.08±0.09** -0.11±0.06**  -0.23±0.05***   0.09±0.05  -0.29±0.07**  -0.54±0.06**  -0.33±0.04  -0.56±0.04** 
n 11 11 11 8 8 8 9 9 9 
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Table 3: Potency (pEC50), affinity (pKa) and coupling efficacy (log τ) values for cAMP production at the CLR co-expressed with each RAMP, stimulated with 
various agonists measured in HEK-293 cells in the presence and absence of pertussis toxin. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Data are the mean ± SEM of n individual data sets. 
a The negative logarithm of the agonist concentration required to produce a half-maximal response. 
b The maximal response to the ligand expressed as a percentage of the maximal cAMP production as determined using 100 µM forskolin stimulation in the presence 
of pertussis toxin treatment. 
c The negative logarithm of the equilibrium disassociation constant for each ligand generated through use of the operational model of agonism (34). 
d τ is the coupling efficiency parameter of each ligand. 
Statistically different between PTX-treated and untreated was determined using Student’s t-test (*, p < 0.05, **, p < 0.01, ***, p < 0.001, ****, p < 0.0001). 
 
 
  
RAMP1 Untreated 
 Treated 
pEC50a Emaxb pKac logτd n  pEC50a Emaxb pKac logτd n 
CGRP 9.66±0.2 47.07±2.2 9.43±0.2 -0.11±0.04 9    9.65±0.2   44.95±2.2!  9.33±0.3!  -0.11±0.07 6 
AM 7.93±0.2 48.06±2.5 7.67±0.2 -0.09±0.05 9    8.14±0.07   72.17±1.7***!  7.66±0.2! - 0.36±0.1** 6!
AM2 7.93±0.2 46.10±4.1 7.70±0.2 -0.11±0.07 9    9.15±0.1*0   72.15±2.4***  8.56±0.3! - 0.40±0.1**! 6 
RAMP2 Untreated 
 Treated 
pEC50a Emaxb pKac logτd n  pEC50a Emaxb pKac logτd n 
CGRP 19.00±0.2 36.97±2.4 18.82±0.2 -0.27±0.05 9  18.25±0.4   56.27±1.4***  7.92±0.2*! 0  0.1±0.06** 6 
AM 10.35±0.1 56.33±1.6 10.00±0.1 -0.07±0.02 9  10.16±0.07   56.07±1.1  9.83±0.2   0.07±0.02 6!
AM2 17.46±0.2 36.61±3.5 17.24±0.2 -0.29±0.07 9  19.13±0.1**   56.05±2.2***  8.84±0.2**   00.1±0.06* 6!
RAMP3 Untreated 
 Treated 
pEC50a Emaxb pKac logτd n  pEC50a Emaxb pKac logτd n 
CGRP 7.75±0.3 22.38±2.6 7.64±0.3 -0.54±0.07 8     8.90±0.1*  32.61±1.5*!   8.74±0.2*  -0.29±0.06 7 
AM 8.98±0.2 32.00±1.5 8.83±0.1 -0.33±0.03 8     9.10±0.2  35.95±2.2!   8.94±0.2!  -0.34±0.05 7!
AM2 9.10±0.2 21.92±1.7 9.08±0.2 -0.51±0.06 8     8.74±0.2  44.35±2.7****   8.43±0.1*  -0.07±0.07*** 7 
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Table 4: Potency (pEC50) and maximal response (Emax), for cAMP production at the CLR co-expressed with each RAMP, stimulated with various agonists measured 
in HEK-293S cells in the presence or absence of pertussis toxin. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Data are the mean ± SEM of n individual data sets. 
a The negative logarithm of the agonist concentration required to produce a half-maximal response. 
b The maximal response to the ligand expressed as a percentage of the maximal cAMP production as determined using 100 µM forskolin stimulation in the presence 
of PTX treatment. 
No statistical difference was found between untreated and PTX-treated HEK-293S cells using Student’s t-test. 
 
 
  
RAMP1 Untreated  Treated pEC50a Emaxb n  pEC50a Emaxb n 
CGRP 9.88±0.1 59.98±1.1 5  9.87±0.1 72.92±2.3! 5 
AM 8.13±0.1 60.00±3.1 5  8.03±0.1 61.26±2.6! 5!
AM2 8.74±0.1 68.94±1.2 5  8.78±0.1 68.30±1.6 5 
RAMP2 Untreated 
 Treated 
pEC50a Emaxb n  pEC50a Emaxb n 
CGRP 8.00±0.1 32.56±1.0 5  7.88±0.1 39.32±1.7 5 
AM 9.39±0.1 30.34±0.8 5  9.38±0.1 33.28±1.2 5!
AM2 8.57±0.1 40.30±1.5 5  18.58±0.16 30.52±2.0 5!
RAMP3 Untreated 
 Treated 
pEC50a Emaxb n  pEC50a Emaxb n 
CGRP 8.42±0.1 40.84±0.6 5  8.38±0.1 39.84±1.0! 5 
AM 9.63±0.1 39.09±1.2 5  9.49±0.2 42.26±1.6! 5!
AM2 8.01±0.1 33.75±1.5 5  7.79±0.2 28.21±2.4 5 
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Table 5: Potency (pEC50), affinity (pKa) and coupling efficacy (log τ) values for i(Ca2+) mobilization at the CLR co-expressed with each RAMP, stimulated with 
various agonists measured in HEK-293 and HEK-293S cells. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Data are the mean ± SEM of n individual data sets. 
a The negative logarithm of the agonist concentration required to produce a half-maximal response. 
b The maximal response to the ligand expressed as a percentage of the maximal i(Ca2+) release as determined using 10 µM ionomycin stimulation. 
c The negative logarithm of the equilibrium disassociation constant for each ligand generated through use of the operational model of agonism (34). 
d τ is the coupling efficiency parameter of each ligand. 
Statistical significance compared to the cognate ligand (*, p < 0.05, **, p < 0.01, ***, p < 0.001, ****, p < 0.0001) for each receptor heterodimer (CGRP for 
RAMP1-CLR; AM for CLR with either RAMP2 or RAMP3) was determined by one-way ANOVA with Dunnett’s post-test. 
 !
RAMP1 
HEK-293  HEK-293S 
pEC50a Emaxb pKac logτd n  pEC50a Emaxb pKac logτd n 
CGRP 8.19±0.1 79.68±0.7 7.50±0.1  0.60±0.05 5      8.06±0.1     67.64±2.0!   7.57±0.1!    0.32±0.04 5 
AM 7.90±0.2 37.00±3.5**** 7.69±0.4 -0.24±0.10 5      7.63±0.2     38.18±3.8****!   7.42±0.2!   -0.21±0.07**** 5!
AM2 6.76±0.2*** 25.05±2.4**** 6.64±0.1** -0.48±0.06** 5      6.94±0.1***     33.28±1.7****   6.76±0.1**!   -0.30±0.03****! 5 
RAMP2 
HEK-293  HEK-293S 
pEC50a Emaxb pKac logτd n  pEC50a Emaxb pKac logτd n 
CGRP  7.86±0.1 63.20±3.0 7.43±0.1  0.54±0.10 5      7.55±0.3     55.35±4.5   7.21±0.3!    0.07±0.08 5 
AM  7.86±0.1 63.00±1.8 7.45±0.2 -0.19±0.06 5      7.68±0.2     52.26±4.5   7.39±0.2    0.03±0.10 5!
AM2  7.41±0.4 44.41±7.1* 7.15±0.4 -0.10±0.13** 5      7.42±0.4     20.17±2.8****   7.33±0.2   -0.65±0.13*** 5!
RAMP3 
HEK-293  HEK-293S 
pEC50a Emaxb pKac logτd n  pEC50a Emaxb pKac logτd n 
CGRP  7.47±0.2* 84.39±8.5* 6.66±0.4*  0.74±0.26 5      7.51±0.2      65.3±4.7!   7.07±0.2**    0.24±0.10* 5 
AM  8.12±0.1 56.69±6.6 7.76±0.3  0.13±0.13 5      8.02±0.2      44.3±3.2!   8.56±0.2!   -0.11±0.06 5!
AM2  8.05±0.3 19.99±2.4* 7.95±0.3* -0.63±0.08* 5      7.44±0.3      20.1±4.3   7.35±0.3**   -0.62±0.07** 5 
Supplementary Movie 1. 
The RAMP2 C-terminus (yellow surface, right hand side) approaches toward Gαs (green 
surface, left hand side) during a molecular dynamics simulations of an active RAMP2-
GCGR-glucagon-Gαs complex. The GCGR (ribbon representation) is coloured according to 
time progression, from red (0 ns) to blue (500 ns). 
 
Supplementary Movie 2. 
The RAMP1 C-terminus (yellow surface, right hand side) approaches toward Gαs (blue 
surface, left hand side) during a 500 ns molecular dynamics simulations of an active RAMP1-
CLR-CGRP-Gαs complex. CLR (ribbon representation) is coloured green. Part of the RAMP 
C-terminus also contacts H8 of CLR. 	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